These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33849967)

  • 21. Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis.
    Veettil SK; Kew ST; Lim KG; Phisalprapa P; Kumar S; Lee YY; Chaiyakunapruk N
    BMC Gastroenterol; 2021 Mar; 21(1):130. PubMed ID: 33743605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
    Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men.
    Pignone M; Earnshaw S; McDade C; Pletcher MJ
    J Gen Intern Med; 2013 Nov; 28(11):1483-91. PubMed ID: 23681842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
    Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S
    Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
    Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
    Magnuson EA; Li H; Wang K; Vilain K; Shafiq A; Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Braunwald E; Sabatine MS; Cohen DJ;
    J Am Coll Cardiol; 2017 Aug; 70(5):527-538. PubMed ID: 28750695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.
    Jiang M; Li P; You JH; Zheng X; Deng J; Zhao M; Feng L; Fang Y
    PLoS One; 2019; 14(12):e0224580. PubMed ID: 31790409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
    Dehmer SP; Maciosek MV; LaFrance AB; Flottemesch TJ
    Ann Fam Med; 2017 Jan; 15(1):23-36. PubMed ID: 28376458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy.
    Pastorino R; Basile M; Tognetto A; Di Marco M; Grossi A; Lucci-Cordisco E; Scaldaferri F; De Censi A; Federici A; Villari P; Genuardi M; Ricciardi W; Boccia S
    PLoS One; 2020; 15(7):e0235038. PubMed ID: 32609729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
    Lin Z; Zhang L; Yang X; Liu L; Xuan J
    J Med Econ; 2020 Jun; 23(6):659-666. PubMed ID: 31999196
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
    Teppala S; Hodgkinson B; Hayes S; Scuffham P; Tuffaha H
    J Med Econ; 2023; 26(1):19-33. PubMed ID: 36426964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
    Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
    Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
    Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
    Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin for Primary Prevention.
    Richman IB; Owens DK
    Med Clin North Am; 2017 Jul; 101(4):713-724. PubMed ID: 28577622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aspirin and Cancer.
    Patrignani P; Patrono C
    J Am Coll Cardiol; 2016 Aug; 68(9):967-76. PubMed ID: 27561771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
    Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.